CTI BioPharma Corp. (CTIC) to Release Earnings on Monday
CTI BioPharma Corp. (NASDAQ:CTIC) is scheduled to post its quarterly earnings results after the market closes on Monday, November 6th. Analysts expect CTI BioPharma Corp. to post earnings of ($0.32) per share for the quarter.
CTI BioPharma Corp. (NASDAQ:CTIC) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The business had revenue of $22.23 million during the quarter. On average, analysts expect CTI BioPharma Corp. to post $-1.26 EPS for the current fiscal year and $-1.87 EPS for the next fiscal year.
Shares of CTI BioPharma Corp. (CTIC) traded down 0.63% during trading on Monday, hitting $3.14. The stock had a trading volume of 87,234 shares. The stock’s 50-day moving average is $3.25 and its 200-day moving average is $3.54. The stock’s market capitalization is $99.62 million. CTI BioPharma Corp. has a 12-month low of $2.70 and a 12-month high of $6.48.
Several brokerages recently issued reports on CTIC. ValuEngine cut CTI BioPharma Corp. from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 11th. Jefferies Group LLC began coverage on CTI BioPharma Corp. in a research note on Tuesday, September 12th. They issued a “buy” rating and a $7.50 price target for the company.
In other CTI BioPharma Corp. news, Director Richard L. Love sold 14,600 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the transaction, the director now directly owns 84,318 shares in the company, valued at $270,660.78. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 8.08% of the company’s stock.
About CTI BioPharma Corp.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.